Irfan Firdaus

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 284 citations · Full text

Medicine, Oncology, Pharmacology +13

A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer

Jordan Berlin, Johanna C. Bendell, Lowell L. Hart et al. · Clinical Cancer Research · 2012 · 177 citations

Medicine, Oncology, Pharmacology +17

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Harry H. Yoon, Johanna C. Bendell, Fadi S. Braiteh et al. · Annals of Oncology · 2016 · 144 citations · Full text

Medicine, Clinical Sciences, Oncology +13

Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial.

Harry H. Yoon, Johanna C. Bendell, Fadi S. Braiteh et al. · Journal of Clinical Oncology · 2014 · 81 citations

Medicine, Oncology, Pharmacotherapy +16

A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

Zishuo Ian Hu, Johanna C. Bendell, Andrea J. Bullock et al. · Cancer Medicine · 2019 · 81 citations · Full text

Medicine, Oncology, Pharmacology +17